Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 3/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.37 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.37 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117351 | 1.00 | PRKAB2 (0.37) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL119331 | 0.85 | GAA (0.50) | KDM4E | |
| SCHEMBL119330 | 0.85 | GAA (0.50) | KDM4E | |
| SCHEMBL3719040 | 0.78 | PTGS1 (0.40) | PRKDCCFTRKDM4ENPSR1PTGS1 | |
| SCHEMBL3719037 | 0.78 | PTGS1 (0.40) | PRKDCCFTRKDM4ENPSR1PTGS1 | |
| SCHEMBL27680972 | 0.69 | RBP4 (0.54) | KDM4EUSP2HPGDNPSR1HSD17B10 | |
| SCHEMBL3340526 | 0.69 | PTGS1 (0.41) | KDM4EPTGS1PTGS2 | |
| SCHEMBL3369735 | 0.69 | PTGS1 (0.41) | KDM4EPTGS1PTGS2 | |
| SCHEMBL2086528 | 0.69 | PTGS1 (0.41) | KDM4EPTGS1PTGS2 | |
| SCHEMBL14655202 | 0.68 | NPC1 (0.52) | CFTRPTGER4KDM4EFGFR1SMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2424866-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS -SECRETASE INHIBITORS | High Point Pharmaceuticals, LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126745-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | PRKAB2 2570/4885PRKAG1 2319/4885PRKAA2 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.